Journal of the American College of Nutrition, Vol 16, Issue 3 280-282, Copyright © 1997 by American College of Nutrition

JOURNAL ARTICLE

Abnormal thyroid function tests in infants with congenital hypothyroidism: the influence of soy-based formula

M. A. Jabbar, J. Larrea and R. A. Shaw
Department of Pediatrics, Hurley Medical Center, Flint, Michigan 48503, USA.

OBJECTIVE: To assess the etiology of hyperthyroxinemia or hyperthyrotropinemia in infants with congenital hypothyroidism who are on replacement therapy with L-thyroxine. METHODS: These infants were treated with recommended doses of L-thyroxine following the diagnosis of congenital hypothyroidism. Because of hyperthyroxinemia (2 patients) and hyperthyrotropinemia (1 patient), medication compliance and dietary practice (formula type, age of introduction, and discontinuation or change of the formula) were assessed. Clinical evaluation was also performed. RESULTS: Elevated thyroxine level in 2 infants was associated with discontinuation of soy formula 4 weeks previously; reduction of L-thyroxine dose normalized serum levels in both of these infants. In the third infant, who received soy formula from 1 week of age, TSH remained elevated despite incremental L-thyroxine doses of 19 micrograms/kg/day; discontinuation of soy formula was followed by normalization of the TSH in 3 weeks and helped attain a subsequent decrement of L-thyroxine dose to 8.6 micrograms/kg/day. Neither the hyperthyroxinemia nor hyperthyrotropinemia in these infants was associated with any adverse behavioral-developmental consequence. CONCLUSION: When initiating soy-formula feeding in infants with congenital hypothyroidism, the L-thyroxine dose should be increased because of significant reduction in intestinal absorption: conversely, when soy feeding is discontinued, the L-thyroxine dose should be decreased.

This article has been cited by other articles:

				E. Diamanti-Kandarakis, J.-P. Bourguignon, L. C. Giudice, R. Hauser, G. S. Prins, A. M. Soto, R. T. Zoeller, and A. C. Gore Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement Endocr. Rev., June 1, 2009; 30(4): 293 - 342. [Abstract] [Full Text] [PDF]

				C. W. Xiao Health Effects of Soy Protein and Isoflavones in Humans J. Nutr., June 1, 2008; 138(6): 1244S - 1249S. [Abstract] [Full Text] [PDF]

				J. Bhatia, F. Greer, and and the Committee on Nutrition Use of Soy Protein-Based Formulas in Infant Feeding Pediatrics, May 1, 2008; 121(5): 1062 - 1068. [Abstract] [Full Text] [PDF]

				D. W. Schiff Soy Formula andthe Management of Congenital Hypothyroidism AAP Grand Rounds, June 1, 2004; 11(6): 68 - 69. [Full Text] [PDF]

				R. J. Merritt and B. H. Jenks Safety of Soy-Based Infant Formulas Containing Isoflavones: The Clinical Evidence J. Nutr., May 1, 2004; 134(5): 1220S - 1224S. [Abstract] [Full Text] [PDF]

				S C Conrad, H Chiu, and B L Silverman Soy formula complicates management of congenital hypothyroidism Arch. Dis. Child., January 1, 2004; 89(1): 37 - 40. [Abstract] [Full Text] [PDF]